Gene · 84444
Papers2,742
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,742
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative Multiomics Insights into the Genetic and Epigenetic Architecture of Alzheimer's Disease. | ACS Chem Neurosci | 2026 | 41422555 | PubTator, text mining | PubMed |
| A medicinal chemistry perspective on disruptor of telomeric silencing 1-like: Its mechanisms and modulators in cancer treatment. | Eur J Med Chem | 2026 | 41380389 | PubTator, text mining | PubMed |
| Berberine Hydrochloride Inhibits the Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells by Regulating Amino Acid Metabolism. | Anticancer Agents Med Chem | 2026 | 41140218 | PubTator, text mining | PubMed |
| Therapeutic targeting of chromatin alterations in leukemia and solid tumors. | Int J Cancer | 2026 | 40181550 | PubTator, text mining | PubMed |
| Research Progress on the KMT2A-AFF3 Fusion Gene in Childhood Acute Lymphoblastic Leukemia: Mechanisms, Clinical Implications, and Therapeutic Strategies. | Curr Issues Mol Biol | 2025 | 41614752 | PubTator, text mining | PubMed |
| Baicalin protects against myocardial fibrosis through inhibition of DOT1L/COL-1 pathway during diabetic cardiomyopathy. | Sci Rep | 2025 | 41444328 | PubTator, text mining | PubMed |
| DOT1L inhibition exerts the anti-tumor effect by activating interferon signaling in breast cancer cells. | Clin Epigenetics | 2025 | 41299712 | PubTator, text mining | PubMed |
| DOT1L as a Therapeutic Target: Insights into Epigenetic Regulation and Cancer Treatment. | Biomol Ther (Seoul) | 2025 | 41169259 | PubTator, text mining | PubMed |
| Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia. | Exp Hematol Oncol | 2025 | 41126315 | PubTator, text mining | PubMed |
| Targeted and epigenetic therapies for acute myeloid leukemia treatment. | Discov Oncol | 2025 | 41003912 | PubTator, text mining | PubMed |
| Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature. | BJC Rep | 2025 | 40983660 | PubTator, text mining | PubMed |
| Post-translational modification of H2B C-terminal helix regulates nucleosome interactions and chromatin signaling. | Nucleic Acids Res | 2025 | 40966523 | PubTator, text mining | PubMed |
| Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction. | Signal Transduct Target Ther | 2025 | 40962819 | PubTator, text mining | PubMed |
| Synthesis, Structure-Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein-Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. | J Med Chem | 2025 | 40957087 | PubTator, text mining | PubMed |
| The MLLT3 YEATS domain is a dual reader of histone marks (H3K9/18/27ac/cr) and ncRNA (7SK), linking epigenetic and RNA signaling to regulate hematopoiesis. | bioRxiv | 2025 | 40950097 | PubTator, text mining | PubMed |
| SETD2 suppresses tumorigenesis in a KRASG12C-driven lung cancer model, and its catalytic activity is regulated by histone acetylation. | Elife | 2025 | 40948406 | PubTator, text mining | PubMed |
| 5'-Methylthioadenosine Metabolic Reprogramming Drives H3K79 Monomethylation-Mediated PAK2 Upregulation to Promote Cadmium-Induced Breast Cancer Progression by Impairing Autophagic Flux. | Adv Sci (Weinh) | 2025 | 40919610 | PubTator, text mining | PubMed |
| Interrogating the regulatory epigenome of cellular senescence. | Cell Mol Life Sci | 2025 | 40886198 | PubTator, text mining | PubMed |
| ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L. | Nat Genet | 2025 | 40858905 | PubTator, text mining | PubMed |
| Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy. | Diabetes Metab Res Rev | 2025 | 40831067 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/84444/papers?page=4